The trajectory of Sildenafil presents a complex case for investors in the drug sector. While initially a tremendous success, generating billions, the intellectual property end and the subsequent arrival of generic competitors have considerably changed earnings. This raises questions about the long-term viability of similar medication projects an… Read More